Abstract
The expression or dysfunction of long non-coding RNAs (lncRNAs) is closely related to various hereditary diseases, autoimmune diseases, metabolic diseases and tumors. LncRNAs were also recently recognized as functional regulators of fibrosis, which is a secondary process in many of these diseases and a primary pathology in fibrosis diseases. We review the latest findings on lncRNAs in fibrosis diseases of the liver, myocardium, kidney, lung and peritoneum. We also discuss the potential of disease-related lncRNAs as therapeutic targets for the clinical treatment of human fibrosis diseases.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Alu Elements
-
Animals
-
Cyclin-Dependent Kinase Inhibitor p21 / genetics
-
Cyclin-Dependent Kinase Inhibitor p57 / genetics
-
Fibrosis / genetics*
-
Fibrosis / metabolism
-
Fibrosis / pathology
-
Humans
-
Kidney / pathology
-
Liver / pathology
-
Lung / pathology
-
Myocardial Infarction / genetics
-
Myocardial Infarction / pathology
-
Myocardium / pathology
-
RNA, Long Noncoding* / genetics
-
Rats
Substances
-
CDKN1A protein, human
-
Cyclin-Dependent Kinase Inhibitor p21
-
Cyclin-Dependent Kinase Inhibitor p57
-
MEG3 non-coding RNA, human
-
RNA, Long Noncoding